Full history for every metric is available with a Kvantra account
Merus N.V. (MRUS)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 24 | 25 | 43 | 39 | 40 | 35 | 53 |
| Operating profit | $m | -263 | -346 | |||||
| Net profit | $m | -43 | -70 | -59 | -123 | -140 | -208 | -349 |
| EPS reported | $ | -3.35 | -5.34 | |||||
| Operating cashflow per share | $ | -2.89 | -3.31 | |||||
| Capex per share | $ | 0.03 | 0.01 | |||||
| FCF per share | $ | -2.92 | -3.32 | |||||
| Free cash flow | $m | -188 | -318 | |||||
| Net debt | $m | -535 | -535 | |||||
| Book value equity | $m | 648 | 662 | |||||
| Book value per share | $ | 10.09 | 8.74 | |||||
| Number of shares | m | 64.22 | 75.68 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 4.17 | 10.32 | |||||
| P/S LTM | x | 77.42 | 128.91 | |||||
| P/FCF LTM | x | -14.40 | -21.47 | |||||
| EV/EBITDA LTM | x | -9.29 | -19.44 | |||||
| EV/Sales LTM | x | 69.30 | 118.80 | |||||
| Earnings Yield LTM | % | -7.70% | -4.68% | |||||
| FCF Yield | % | -6.94% | -4.66% | |||||
| Quality | ||||||||
| ROE | % | -32.08% | -45.59% | |||||
| ROIC | % | -37.66% | -37.15% | |||||
| Operating margin | % | -752.96% | -589.59% | |||||
| Gross margin | % | 37.15% | -249.98% | |||||
| FCF/Sales | % | -537.58% | -569.25% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -12.38% | +61.31% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -18.92 | -30.23 | |||||
| Net Debt/EBITDA | x | 1.09 | 1.27 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -19.82% | -7.84% | |||||
| Net debt/Equity | x | -0.83 | -0.81 | |||||
| Gross debt/equity | x | 0.02 | 0.02 | |||||
Company overview
Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158: In Phase 1 clinical trials for solid tumors. MCLA-145: Also in Phase 1 clinical trials for various solid tumors. MCLA-129: Progressing through Phase 1/2 clinical trials for advanced non-small cell lung cancer (NSCLC) and other solid tumors. ONO-4685: Currently in Phase 1 clinical trials to address relapsed/refractory T-cell lymphoma. Furthermore, Merus engages in strategic partnerships. It collaborates with Betta Pharmaceuticals Co. Ltd on the research and development of specific bispecific antibody candidates, including MCLA-129. Additionally, Incyte Corporation is partnering with Merus for the development of MCLA-145.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Merus N.V. (MRUS)
Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158: In Phase 1 clinical trials for solid tumors. MCLA-145: Also in Phase 1 clinical trials for various solid tumors. MCLA-129: Progressing through Phase 1/2 clinical trials for advanced non-small cell lung cancer (NSCLC) and other solid tumors. ONO-4685: Currently in Phase 1 clinical trials to address relapsed/refractory T-cell lymphoma. Furthermore, Merus engages in strategic partnerships. It collaborates with Betta Pharmaceuticals Co. Ltd on the research and development of specific bispecific antibody candidates, including MCLA-129. Additionally, Incyte Corporation is partnering with Merus for the development of MCLA-145.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free